Pegaptanib

Pegaptanib is a selective vascular endothelial growth factor (VEGF) antagonist. It is a pegylated anti-VEGF aptamer, a single strand of nucleic acid that binds to the major pathological VEGF isoform, extracellular VEGF165, thereby inhibiting VEGF165 binding to VEGF receptors. VEGF165 induces angiogenesis and increases vascular permeability and inflammation, all of which are thought to contribute to the progression of the neovascular (wet) form of ARMD.

Adult

0.3 mg by intravitreal injection. Dose levels higher than 0.3 mg did not demonstrate additional benefit.

Max dose

0.3 mg